Dr. Hua Ling received his Doctor of Pharmacy degree from Nova Southeastern University in Fort Lauderdale, Florida. After graduation, Dr. Ling moved to Omaha, Nebraska where he completed an ACCP-accredited two-year pharmacy fellowship specializing in cardiology at Creighton University Medical Center. Prior to joining GA-PCOM, he served as an assistant professor at Hampton University School of Pharmacy.
Dr. Ling’s practice and research interests include cardiovascular disease, chronic disease management and medication adherence. During his professional career, he has primarily worked in outpatient settings to provide clinical pharmacy services to serve the needs of medication management and transitional care management. His research work, including collaborations with students, has been published in several peer-reviewed journals and national conferences. He is an active member of ACCP, AACP and AHA.
Ling H*, Andrews E, Ombengi D, Li F. Extended Duration Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Peripheral Arterial Disease: A Meta-Analysis. Cardiology Research. 2018;9(3):137-143
Li F, Zheng C, Xin J, Chen F, Ling H, Sun L, Webster TJ, Ming X, Liu J. Enhanced tumor delivery and antitumor response of doxorubicin loaded albumin nanoparticles formulated based on a Schiff base. International Journal of Nanomedicine. 2016 Aug; Vol 11; 3875-3890.
Henry C, Lyon R, Ling H*. Clinical Efficacy and Safety of Evolocumab for LDL Cholesterol Reduction. Journal of Vascular Health and Risk Management. 2016, 12:163-169.
Ling H*, Burns T, Hilleman D. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low density lipoprotein cholesterol. Cardiovasc Ther. 2014 Apr;32(2):82-8.
Ling H, Packard K, Burns T, Hilleman D. Impact of Ranolazine on Clinical Outcomes and Health Care Resource Utilization in Patients with Refractory Angina Pectoris. American Journal of Cardiovascular Drugs (2013): 1-6.
Burns T, Ruckman J, Ling H, Washington-Krauth S, Hilleman D, Mohiuddin S. Current State of United States Tobacco Control Initiatives. World Medical & Health Policy 5, no. 3 (2013): 245-259.
Ling H, Luoma J, Hilleman D. A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations. Cardiology Research 4.2 (2013): 47-55.
Ling H*, Lenz T, Burns T, Hilleman D. Reducing the Risk of Obesity: Defining the Role of Weight Loss Drugs. Pharmacotherapy. 2013 Dec;33(12):1308-21.
Ling H*, Burns T, Hilleman D. Novel Strategies for Managing Dyslipidemia: Treatment Beyond Statins. Postgraduate Medicine. 2012 Nov;124(6):43-54.
Hawkins E, Ling H, Burns T, Mooss A, Hilleman D. Aliskiren in Patients Failing to Achieve Blood Pressure Targets with Angiotensin Converting Enzyme Inhibitors or Angiotensin Receptor Blockers. Cardiology Research. 2012 Aug;3(4): 147-153.
Gu H, Wang X, Rao S, Wang J, Zhao J, Ren FL, Mu R, Yang Y, Qi Q, Liu W, Lu N, Ling H, You Q, Guo Q. Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells. Mol Cancer Ther. 2008 Oct;7(10):3298-305.
Gu H, You Q, Liu W, Yang Y, Zhao L, Qi Q, Zhao J, Wang J, Lu N, Ling H, Guo Q, Wang X. Gambogic acid induced tumor cell apoptosis by T lymphocyte activation in H22 transplanted mice. Int Immunopharmacol. 2008 Nov;8(11):1493-502.
Qi Q, Gu H, Yang Y, Lu N, Zhao J, Liu W, Ling H, You QD, Wang X, Guo Q. Involvement of matrix metalloproteinase 2 and 9 in gambogic acid induced suppression of MDA-MB-435 human breast carcinoma cell lung metastasis. J Mol Med (Berl). 2008 Dec;86(12):1367-77.
Williams B, Hamilton A, Ling H*. Clinical Update: Recent Advances in the Clinical
Development of Pro-protein Convertase Subtilisin Kexin 9 Inhibitors. The Heartbeat
Annual Newsletter 2014, ACCP Cardiology Practice and Research Networks.
Ling H, Lee J, Cooley M, Ayoung-Chee R, Hernandez J. Effect of Ezetimibe Added to High-intensity Statin Therapy in Patients with Hypercholesterolemia: A Meta-Analysis. 2018 AHA QCOR meeting, Apr 2018; Arlington, VA.
Ombengi D, Mendez C, Walker R, Ling H. Statin therapy use estimates in diabetic patients with or without cardiovascular disease (CVD) and other CVD risks in the USA: national health and nutrition examination survey 2009-2014. The 11th Health Disparities Conference, Apr 2018; New Orleans, LA.
Ling H, Andrews E, Ombengi D, Brown D. Extended duration dual antiplatelet therapy after percutaneous coronary intervention in patients with peripheral arterial disease: a meta-analysis. 2017 ACCP Annual Meeting, Oct 2017; Phoenix, AZ
Andrews E, Ling H, Parker S, Brown-Hughes T. Role of the Virtual Pharmacists on an Interprofessional Transitional Care Team. 2017 ASCP’s Annual Meeting & Exhibition, Nov 2017; Orlando, FL
Jariwala I, Ling H. Grant Record of Clinical Faculty in the Department of Pharmacy Practice. 2016 Midyear Clinical Meeting, Dec 2016; Las Vegas, NV
Ling H, Topalli S, Li F, Ndemo F, Ombengi D. Publication Records of Pharmacy Practice Chairpersons: A 5-Year Analysis. 2016 ACCP Annual Meeting, Oct 2016; Ft Lauderdale, FL.
Brown D, Ombengi D, Ling H. Impact of Pharmacists' Interventions on Readmission Rate within 12 months after Discharge in Heart Failure Patients: a meta-analysis. Pharmacotherapy. 2014 Vol. 34, No. 10, pp. E265-E265
Hilleman D, Ling H, Luoma J. A Review and Comparison of Fenofibrate and Fenofibric Acid Formulations Available in the United States. American Pharmacists Association (APhA) Annual Meeting & Exposition; Mar 2013; Los Angeles, CA. Abstract 31.
Malesker M, Boldt D, Ling H, Burns T, Hilleman D. Impact Of The ACCP Antithrombotic Guidelines On Potential Utilization Of Dabigatran In Patients With Atrial Fibrillation. Chest. 2013;144:161A-161A.
Ling H, Nicklaus M, Burns T. A novel strategy for smoking cessation: where does your butt go? 2012 ASHP Midyear Meeting & Exhibition; December 2012; Las Vegas, NV.
Ling H, Packard K, Burns T, Hilleman D. Impact of Ranolazine on Clinical Outcomes and Health Care Resource Utilization in Patients with Angina Pectoris. Circulation. 2012; 126: A11785
Hawkins E, Ling H, Burns T, Hilleman D. Perceptions, Knowledge, and Patterns of Use of “Fish Oil” Products in Cardiac Patients. Pharmacotherapy, 2012;32(10):e184
Hawkins E, Ling H, Burns T, Mooss A, Hilleman D. Aliskiren in Patients Failing to Achieve Blood Pressure Targets with Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers. Pharmacotherapy, 2012;32(10):e184
Hilleman D, Ling H, Luoma J. A Review and Comparison of Fenofibrate and Fenofibric Acid Formulations Available in the United States. 27th National Conference of the American Academy of Nurse Practitioners; June 2012; Orlando, FL. Abstract 24.
Ling H. Risk Control for Heart Attack & Stroke in Patients with Diabetes Mellitus. Hampton University's 37th Annual Conference on the Black Family; Hampton University, Hampton, VA; Mar 2015.
Ling H. Recent Advances in the Clinical Development of Proprotein Convertase Subtilisin Kexin 9 Inhibitors. 2014 Virginia Society of Health-System Pharmacists Fall Seminar; Oct 25, 2014.
Ling H. New obesity drugs, Presented at the Cardiac Center. Cardiology Grand Rounds; Creighton University Medical Center, Omaha, NE, Mar 2013.
Ling H. Novel Strategies for Managing Dyslipidemia: Treatment Beyond Statins, Presented at the Cardiac Center. Cardiology Grand Rounds; Creighton University Medical Center, Omaha, NE, Mar 2012.
Ling H. Pharmacogenetic Testing in Warfarin Dosing. Pharmacy Grand Rounds; Creighton University Medical Center, Omaha, NE, Dec 2011.